



Efficient and rapid conversion of 3-amino-imidazo [1,2-*a*]pyridin-2-yl-4H-chromene-4-ones to its corresponding thio analogues using Lawesson's reagent †

M V Basavanag Unnamatla¹, Rocío Gámez Montaño^{*}

¹Departamento de Química, División de Ciencias Naturales y Exactas, Universidad de Guanajuato, Noria Alta S/N, Col. Noria Alta, Guanajuato, C.P. 36050 Guanajuato, México 1; <u>muralivenkat@ugto.mx</u>
*Departamento de Química, División de Ciencias Naturales y Exactas, Universidad de Guanajuato, Noria Alta S/N, Col. Noria Alta, Guanajuato, C.P. 36050 Guanajuato, México: <u>rogammo@gmail.com</u>; Tel.: +52-473-732-0006. Ext: 8191. Presented at the title, place, and date.

Received: date; Accepted: date; Published: date

Abstract: An expeditious, efficient and high yield conversion of ketone group in GBB adducts was obtained by the reaction with 3-formyl chromone, 2-amino pyridine and isocyanide to corresponding thio analogues is described utilizing Lawesson's reagent. The reaction was involved microwave irradiation for both GBBR and the functional group transformation from ketone to thio ketone using Lawesson's reagent through sequential fashion. The thio heterocyclic analogs of GBB products were characterized by using NMR.

Keywords: GBB reaction; Lawesson's reagent; 3-formyl chromone.

1. Introduction

Chromones and its thio analogues are privileged molecules and these have considerable attention now a days due to their potential biological applications [1] such as antiproliferative **Figure 1**[2], antiangiogenic activity [3] The functional group transformation from oxygen to its thio analogues of ketones, flavones have considerable attention now a days due to their biological importance of these molecules [4]. Organosulfur compounds have unique place in synthetic organic chemistry due to their rich and versatile chemistry [5]. Thionation, the functional group transformation carbonyl group to thiocarbonyl is broadly applied procedure in synthesis of organosulfur compounds. This transformation has been accomplished by several reagents especially phosphorous pentasulfide [6], bis(trimethylsilyl) sulfide with CoCl₂,6H₂O [7], and thiation of gemdichlorides with sodium hydrogen sulfide [8],



Figure 1: Bioactive thiooxoflavonoids

The above process involves lengthy procedures and require excess of reagents, aromatic hydrocarbon-based solvents benzene, toluene under dry conditions affording only moderate yields. The Lawesson's reagent, 2,4-bis(pmethoxyphenyl)-1,3-dithiaphosphetane2,4-disulfide has been commonly used for efficient transformation of oxygen group to their thio analogues [9].

Here in we present an efficient rapid conversion of 3-amino-imidazo[1,2-*a*]pyridine-2-yl-4Hchromene-4-ones **[10]** to its corresponding thio analogues. In continuation of our research we report the combination of Groebke– Blackburn–Bienaymé **[11]** IMCR with Lawesson's reagent conversion of carbonyl to thiocarbonyl group as post transformation process (Scheme1). The present work gives scope and diversity in obtaining variation in Bis-heterocycles via IMCR. As in our research group of investigation had significant progress in GBBR obtaining Bis-heterocycles. So, this contribution of using Lawesson's reagent in IMCR strategy are hitherto unreported. The GBB adducts were obtained by the reaction with 3-formyl chromone, 2-amino pyridines, and Isocyanide. In this reaction we combine two privileged molecules were bound to form a Bis-heterocycle where the chromone based GBB adduct (**4a**, **4b**) carbonyl group were transformed to its thio analogues (**5a**,**5b**). under microwave irradiation.



Scheme1 Synthesis of thio analogues of 3-amino-imidazo[1,2-a]pyridine-2-yl-4H-chromene-4-ones.

The two privileged structures were bound were separately represents as pharmacophores whereas the chromone present a vast biological activity such as antioxidants [12], anti-HIV [13], antitumoral [14], anticancer [15], antiviral [16] antiasthmatics [17], anti-Parkinson [18], antiallergics [19] and as antimicrobials [20]. On the other hand imidazo[1,2-*a*]pyridine also have a broad spectrum of biological activities such as anticancer [21], antiviral [22], antimicrobials [23], anti-Parkinson [24], antimutagenics [25] and as anti-inflammatory [26]. For example, the zolpidem is the most prescribed drug for insomnia [27]. Due the importance of these pharmacological properties and our interest in developing novel molecules and their functionalization by modifying groups that gives promising feature for biological activity. This is reason we use the post transformation as thiocarbonyl conversion using Lawesson's reagent.

2. Results and Discussion.

The reaction is conducted in two step process initially we obtained GBB adducts according to one our recent literature reports mentioned by K.G Kishore *et al.* [28].



Scheme 2: Synthesis of 3-amino-imidazo[1,2-*a*]pyridine-2-yl-4H-chromene-4-ones.

There we blindly used the same conditions and reproduced **4a**, **4b** derivatives, the advantage of this method was acid free and catalyst free reaction under microwave irradiation. Here we have 100% conversion the isolated yield was above 90% for the mentioned derivatives. (**Scheme 2**). The second step involves the transformation of carbonyl to its thio carbonyl group. (**Scheme 3**).



Scheme: 3 Synthesis of thio analogues of 3-amino-imidazo[1,2-a]pyridine-2-yl-4H-chromene-4-ones.

For the basic transformation of carbonyl to its thio carbonyl formation we used Lawesson's reagent (2,4-bis(pmethoxyphenyl)-1,3-dithiaphosphetane2,4-disulfide). Initially as reaction model we use **5a** for reaction optimization under conventional reflux and according to recent literature procedures mentioned by Varma *et al.* [3] for obtaining the thiocarbonyl derivative mention in the **Table 1.** However conventional methods usually require excess of Lawesson's reagent and (0.5- 1 molar equiv) in lengthy reactions (more than 25h) under elevated temperatures and results in low conversion and low isolation yield. To get rid of the above disadvantages we applied microwaves as irradiation source. The advantages of microwave -expedited functional group transformation are cleaner reactions, shorter reaction times and ease of manipulation. Here in we developed the efficient conversion of carbonyl group GBB adduct 4a, 4b to their thio analogue under microwave irradiation. In this reaction process we have used only 0.5 equivalents of Lawesson's reagent and the 4a we have used 1 equiv.



Table 1. Optimization of the reaction using Lawesson's reagent.

LR (Equiv)	TIME	%YIELD
0.5	rt, 48hrs	NR
0.5	reflux, 24hrs	30%
0.8	reflux, 48hrs	30%
0.5))), 3hrs	50%
0.5	MW, 20 min	95%

The reaction progress was monitored by TLC using 6:4 hexane/Ethyl Acetate as eluent. After optimizing reaction, we have characterized the compound with ¹HNMR & ¹³C NMR. Mainly the product conversion was observed clearly in ¹³C NMR where we can observer the change of chemical

shift from C=O is δ 176.7 ppm to C=S is δ 198.34 ppm with respect to CDCl₃ as internal reference confirms the transformation of carbonyl to its thio analogue.

In summary we have developed new methodology with efficient and rapid conversion of 3amino-imidazo[1,2-*a*] pyridine-2-yl-4H-chromene-4-ones to its thio analogues under microwave irradiation using Lawesson's reagent in good to excellent yields.

Supplementary Materials: The following are available online at http://www.xxxxx, Figure S1: title, Table S1: title, Video S1: title.

Author Contributions: All authors contributed equally to this work.

Funding: Authors are grateful for financial support from the CONACYT for financial support CONACYT CB-2016-285622 and DAIP-UG 193/2018 projects.

Acknowledgments: R.G.M & U.M.V.-B. (ID: 32510) thanks to Universidad de Guanajuato Laboratorio, Nacional de Caracterización de Propiedades Fisicoquímícas y Estructura Molecular (CONACYT-México, Project: 123732). The authors are grateful to the Universidad de Guanajuato for access to the single-crystal analysis facility (award No. DAIP-1105/2016), (INFR-2014-01-225496) for the instrumentation time provided.

Conflicts of Interest: The authors declare no conflict of interest.

3. Appendix A

3. 1 Materials and Methods:

General Information. ¹H and ¹³C NMR spectra were acquired on 400 or 500 MHz Bruker Avance III HD spectrometers. The solvent for NMR samples was CDCl3. Chemical shifts are reported in parts per million (δ /ppm). Internal reference for NMR spectra is TMS at 0.00 ppm. Coupling constants are reported in Hertz (J/Hz). Multiplicities of the signals are reported using the standard abbreviations: singlet (s), doublet (d), triplet (t), quartet (q) and multiplet (m). IR spectra were recorded by ATR method using neat compounds. The wavelengths are reported in reciprocal centimeters (vmax /cm–1). HRMS spectra were acquired via electrospray ionization ESI (+) and recorded via the TOF method. Reactions in heating were performed in vials placed into a water bath of a Branson 1510 sonicator cleaner working at 42 kHz ± 6% frequencies. The reaction progress was monitored by TLC and the spots were visualized under UV light (254 or 365 nm). Flash column chromatography was performed using silica gel (230–400 mesh) and mixtures in different proportions of hexanes with ethyl acetate as mobile phase. Melting points were determined on a Fisher-Johns apparatus and were uncorrected.

4. Experimental Section:

4.1 General Procedure for synthesis of 4a-b:

In a MW sealed-tube equipped with a magnetic stirring bar, to a 0.5 M solution of aldehyde (1.0 equiv.) in anhydrous toluene [0.5 M], amine (1.0 equiv.) and isocyanide (1.0 equiv.) were added sequentially and the reaction mixture was MW-heated (100 °C, 150 W) for 10 minutes. Then, the solvent was removed until dryness and the crude were immediately purified by silica-gel column chromatography using a mixture of hexanes with ethyl acetate (7/3; v/v) to afford the corresponding products.

4.2 Synthesis and characterization of selected 3-(3-(tert-butylamino)imidazo[1,2-*a*]pyrdin-2-yl)-4H-chromen-4-one (**4a**):

According to GP 3-Formylchromone (1 mmol, 1 equiv), 2-aminopyridine (1mmol, 1 equiv) and isocyanide were sequentially added and reacted together to afford **4a** of 98% as pale-yellow solid; mp = 206 °C; R_f = 0.17 (hexane-EtOAc 7:3 v/v). *Spectral data for compd* **4a**: FT-IR (ATR)mmax/cm⁻¹ 3281,

2966, 2926, 1629, 1138; 1H NMR (400 MHz; CDCl₃; 25 C; TMS): d 8.80 (s, 1 H), 8.36 (d, *J* = 7.0 Hz, 2 H), 7.73–7.67 (m, 1 H), 7.55 (d, *J* = 8.4 Hz, 1 H), 7.51–7.42 (m, 2 H), 7.16–7.10 (m, 1 H), 6.78–6.73 (m, 1 H), 4.70 (bs, 1 H), 1.05 (s, 9 H); 13C NMR (100 MHz, CDCl₃; 25 C; TMS): d 176.7, 156.6, 156.4, 142.7, 133.9, 130.4, 128.2, 126.5, 125.5, 124.4, 124.3, 124.1, 121.6, 118.1, 116.9, 111.0, 56.0, 29.3; HRMS (ESI+): *m/z* calcd for C₂₀H₂₀N₃0₂+334.1556, found 334.1553.

4.3 General procedure for synthesis of 5a-b

In a MW sealed-tube equipped with a magnetic stirring bar, to 1 equiv of 4a in a solution of toluene 0.5 equiv of LR was added and the reaction mixture was heated (100 °C, 200W) for 20 minutes. Then the solvent was removed under reduced pressure and the crude was purified by silicon-gel column chromatography using the mixture of 6:4 hexane/EtOAc v/v. to afford corresponding thio analogues.

4.3.1 Synthesis and characterization of selected 3-[3-(tert-butylamino)imidazo[1,2-a]pyridin-2-yl]-4H-chromene-4-thione **5a**:

According to GP 4a and LR were reacted to afford 5a in 95% as reddish brown sticky substance ¹H NMR (500 MHz, Chloroform-*d*) δ 8.77 (d, *J* = 8.3 Hz, 1H), 8.52 (s, 1H), 8.37 (d, *J* = 6.9 Hz, 1H), 7.75 (t, *J* = 7.7 Hz, 1H), 7.57 (d, *J* = 8.4 Hz, 1H), 7.53 – 7.46 (m, 2H), 7.18 – 7.14 (m, 1H), 6.79 (t, *J* = 6.8 Hz, 1H), 3.63 (s, 1H), 1.01 (s, 8H). ¹³C NMR (126 MHz, CDCl₃) δ 198.31, 150.85, 150.53, 142.25, 133.79, 131.94, 130.91, 129.51, 127.19, 126.57, 124.18, 123.55, 118.54, 116.99, 111.23, 55.79, 29.74.

4.3.2 Synthesis and characterization of selected 3-[3-(tert-butylamino)-7-methylimidazo[1,2-a]pyridin-2-yl]-4H-chromene-4-thione **5b**:

According to GP 4b and LR were reacted to afford 5b in 92% as reddish-brown sticky substance.

¹H NMR (500 MHz, Chloroform-*d*) δ 8.77 (d, *J* = 8.2 Hz, 1H), 8.51 (s, 1H), 8.23 (d, *J* = 7.0 Hz, 1H), 7.77 – 7.72 (m, 0H), 7.57 (d, *J* = 7.3 Hz, 0H), 7.49 (t, *J* = 7.6 Hz, 1H), 7.25 (d, *J* = 9.3 Hz, 2H), 6.62 (d, *J* = 7.0 Hz, 1H), 3.60 (s, 1H), 2.40 (s, 3H), 1.00 (s, 9H). ¹³C NMR (126 MHz, CDCl₃) δ 198.48, 151.16, 150.78, 142.82, 134.00, 129.78, 126.80, 123.07, 118.80, 115.42, 114.32, 55.98, 29.98, 21.47.

References

- 1. Ellis G. P., The Chemistry of Heterocyclic Compounds, Ed. Wiley, New York, 1977, 31.
- Ravishankar, D.; Watson, K.A.; Boateng, S.Y.; Green, R.J.; Greco, F.; Osborn, H.M.I. Exploring quercetin and luteolin derivatives as antiangiogenic agents. *Eur. J. Med. Chem.* 2015, 97, 259–274, DOI:10.1016/j.ejmech.2015.04.056.
- 3. Varma, R.S.; Kumar, D. Microwave-Accelerated Solvent-Free Synthesis of Thioketones, Thiolactones, Thioamides, Thionoesters, and Thioflavonoids. *Org. Lett.* **1999**, *1*, 697–700, DOI:10.1021/ol990629a.
- 4. Semwal, D.K.; Semwal, R.B.; Combrinck, S.; Viljoen, A. Myricetin: A Dietary Molecule with Diverse Biological Activities. *Nutrients* **2016**, *8*, 90, DOI:10.3390/nu8020090.
- 5. Cremlyn, R. J. An Introduction to Organosulfur Chemistry; John Wiley & Sons: New York, 1996.
- 6. [a] Scheeren, J.W.; Ooms, P.H.J.; Nivard, R.J.F. A General Procedure for the Conversion of a Carbonyl Group into a Thione Group with Tetraphosphorus Decasulfide. *Synthesis (Stuttg).* **1973**, 1973, 149–151, DOI:10.1055/s-1973-22150.
- Capperucci, A.; Degl'Innocenti, A.; Ricci, A.; Mordini, A.; Reginato, G. Silicon-assisted synthesis of thiocarbonyl derivatives and reactivity of dienophilic thioaldehydes. *J. Org. Chem.* 1991, *56*, 7323–7328, DOI:10.1021/jo00026a025.
- 8. Staudinger, H.; Freundenberger, H. Organic Syntheses; Wiley: New York, 1943; Collect. Vol. II, p 573.
- [a] Cava, M.P.; Levinson, M.I. Thionation reactions of lawesson's reagents. *Tetrahedron* 1985, 41, 5061–5087, DOI:10.1016/S0040-4020(01)96753-5 [b] Jones, B.A.; Bradshaw, J.S. Synthesis and reduction of thiocarboxylic O-esters. *Chem. Rev.* 1984, 84, 17–30, DOI: 10.1021/cr00059a002. [c] cheibye, S.; Shabana, R.; Lawesson, S.-O.; Rømming, C. Studies on organophosphorus compounds—XL: Reactions of ketones with 2,4-bis(4-methoxyphenyl)-1,3,2,4-dithiadiphosphetane 2,4-disulfide. *Tetrahedron* 1982, 38, 993–1001, DOI:10.1016/0040-4020(82)85078-3. [d] Shridhar, D.R.; Reddy Sastry, C. V; Vishwakarma, L.C.; Narayan, G.K.A.S.S. An improved procedure for the conversion of 2h-(1, 4)-benzo-thiazin- and 2h-(1, 4)-benzoxazin-3(4h)-ones into 3(4h)-thiones. *Org. Prep. Proced. Int.* 1980, 12, 203–206, DOI:10.1080/00304948009458549.

- 10. Kishore K, Basavanag U, Islas-Jácome A, G.-M.R. Synthesis of imidazo[1,2-*a*]pyridin-chromones by a {MW} assisted Groebke–Blackburn–Bienaymé process. *Tetrahedron Lett.* **2015**, DOI :10.1016/j.tetlet.2014.11.047.
- [a] Claudio-Catalán, M.Á.; Pharande, S.G.; Quezada-Soto, A.; Kishore, K.G.; Rentería-Gómez, A.; Padilla-Vaca, F.; Gámez-Montaño, R. Solvent- and Catalyst-Free One-Pot Green Bound-Type Fused Bis-Heterocycles Synthesis via Groebke–Blackburn–Bienaymé Reaction/SNAr/Ring-Chain Azido-Tautomerization Strategy. ACS Omega 2018, 3, 5177–5186, DOI:10.1021/acsomega.8b00170. [b] Kurva, M.; Pharande, S.G.; Quezada-Soto, A.; Gámez-Montaño, R. Ultrasound assisted green synthesis of bound type bis-heterocyclic carbazolyl imidazo[1,2-a]pyridines via Groebke-Blackburn-Bienayme reaction. *Tetrahedron Lett.* 2018, *59*, 1596–1599, DOI:10.1016/j.tetlet.2018.03.031. [c] Basavanag, U.M. V; Islas-Jácome, A.; Rentería-Gómez, A.; Conejo, A.S.; Kurva, M.; Jiménez-Halla, J.O.C.; Velusamy, J.; Ramos-Ortíz, G.; Gámez-Montaño, R. Synthesis of 2-julolidin-imidazo[1,2-a]pyridines via Groebke–Blackburn–Bienaymé reaction and studies of optical properties. *New J. Chem.* 2017, *41*, 3450–3459, DOI:10.1039/C6NJ04044F. [d] M. V. Basavanag Unnamatla⁺, Alejandro Islas-Jácome⁺, Andrea Quezada-Soto⁺, Sandra C. Ramírez-López⁺, Marcos Flores-Álamo⁺, and R.G.-M. Multicomponent one pot synthesis of 3-tetrazolyl and 3-imidazo[1,2-a]pyridin tetrazolo[1,5-a]quinolines. *J. Org. Chem.* 2016, *81*, 10576–10583, DOI:10.1021/acs.joc.6b01576.
- 12. Semwal, D.K.; Semwal, R.B.; Combrinck, S.; Viljoen, A. Myricetin: A Dietary Molecule with Diverse Biological Activities. *Nutrients* **2016**, *8*, 90, DOI:10.3390/nu8020090.
- 13. Es-Safi, N.-E.; Ghidouche, S.; Ducrot, P.H. Flavonoids: Hemisynthesis, Reactivity, Characterization and Free Radical Scavenging Activity. Molecules 2007, 12, 2228-2258. DOI: 10.3390/12092228.
- 14. Saija, A.; Scalese, M.; Lanza, M.; Marzullo, D.; Bonina, F.; Castelli, F. Flavonoids as antioxidant agents: Importance of their interaction with biomembranes. *Free Radic. Biol. Med.* **1995**, *19*, 481–486, DOI: 10.1016/0891-5849(94)00240-K.
- Yu, D.; Brossi, A.; Kilgore, N.; Wild, C.; Allaway, G.; Lee, K.-H. Anti-HIV Agents. Part 55:††For part 54, see: J. Wu, S. L. Morris-Natschke and K. H. Lee, J. Chin. Chem. Soc., Submitted for publication. 3'R,4'R-Di-(O)-(–)-camphanoyl-2',2'-dimethyldihydropyrano[2,3-f]chromone (DCP), a Novel Anti-HIV agent. *Bioorg. Med. Chem. Lett.* 2003, 13, 1575–1576, DOI:10.1016/S0960-894X(03)00201-4.
- 16. Huang, W.; Liu, M.-Z.; Li, Y.; Tan, Y.; Yang, G.-F. Design, syntheses, and antitumor activity of novel chromone and aurone derivatives. *Bioorg. Med. Chem.* 2007, *15*, 5191–5197, DOI: 10.1016/j.bmc.2007.05.022.
- Barve, V.; Ahmed, F.; Adsule, S.; Banerjee, S.; Kulkarni, S.; Katiyar, P.; Anson, C.E.; Powell, A.K.; Padhye, S.; Sarkar, F.H. Synthesis, Molecular Characterization, and Biological Activity of Novel Synthetic Derivatives of Chromen-4-one in Human Cancer Cells. J. Med. Chem. 2006, 49, 3800–3808, DOI:10.1021/jm051068y.
- 18. Desideri, N.; Conti, C.; Mastromarino, P.; Mastropaolo, F. Synthesis and Anti-Rhinovirus Activity of 2-Styrylchromones. *Antivir. Chem. Chemother.* **2000**, *11*, 373–381, DOI:10.1177/095632020001100604.
- 19. Venkateswararao, E.; Sharma, V.K.; Lee, K.-C.; Roh, E.; Kim, Y.; Jung, S.-H. Design and synthesis of novel chromenone derivatives as interleukin-5 inhibitors. *Bioorg. Med. Chem.* **2013**, *21*, 2543–2550, DOI: 10.1016/j.bmc.2013.02.037.
- 20. Legoabe, L.J.; Petzer, A.; Petzer, J.P. Selected chromone derivatives as inhibitors of monoamine oxidase. *Bioorg. Med. Chem. Lett.* **2012**, *22*, 5480–5484, DOI: 10.1016/j.bmcl.2012.07.025.
- [a] Li, G.-Y.; Jung, K.H.; Lee, H.; Son, M.K.; Seo, J.; Hong, S.-W.; Jeong, Y.; Hong, S.; Hong, S.-S. A novel imidazopyridine derivative, HS-106, induces apoptosis of breast cancer cells and represses angiogenesis by targeting the PI3K/mTOR pathway. *Cancer Lett.* 2013, *329*, 59–67, DOI: 10.1016/j.canlet.2012.10.013. [b] Emmitte, K.A.; Wilson, B.J.; Baum, E.W.; Emerson, H.K.; Kuntz, K.W.; Nailor, K.E.; Salovich, J.M.; Smith, S.C.; Cheung, M.; Gerding, R.M.; Stevens, K.L.; Uehling, D.E.; Mook, R.A.; Moorthy, G.S.; Dickerson, S.H.; Hassell, A.M.; Anthony Leesnitzer, M.; Shewchuk, L.M.; Groy, A.; Rowand, J.L.; Anderson, K.; Atkins, C.L.; Yang, J.; Sabbatini, P.; Kumar, R. Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R). *Bioorg. Med. Chem. Lett.* 2009, *19*, 1004–1008, DOI: 10.1016/j.bmcl.2008.11.058. [c] Jaramillo, C.; de Diego, J.E.; Hamdouchi, C.; Collins, E.; Keyser, H.; Sánchez-Martínez, C.; del Prado, M.; Norman, B.; Brooks, H.B.; Watkins, S.A.; Spencer, C.D.; Dempsey, J.A.; Anderson, B.D.; Campbell, R.M.; Leggett, T.; Patel, B.; Schultz, R.M.; Espinosa, J.; Vieth, M.; Zhang, F.; Timm, D.E. Aminoimidazo[1,2-a]pyridines as a new structural class of cyclin-dependent kinase inhibitors. Part 1: Design, synthesis, and biological evaluation. *Bioorg. Med. Chem. Lett.* 2004, *14*, 6095–6099, DOI: 10.1016/j.bmcl.2004.09.053.

- 22. Hamdouchi, C.; Ezquerra, J.; Vega, J.A.; Vaquero, J.J.; Alvarez-Builla, J.; Heinz, B.A. Short synthesis and anti-rhinoviral activity of imidazo[1,2-a]pyridines: The effect of acyl groups at 3-position. *Bioorg. Med. Chem. Lett.* **1999**, *9*, 1391–1394, DOI:10.1016/S0960-894X(99)00193-6.
- [a] Shukla, N.M.; Salunke, D.B.; Yoo, E.; Mutz, C.A.; Balakrishna, R.; David, S.A. Antibacterial activities of Groebke–Blackburn–Bienaymé-derived imidazo[1,2-a]pyridin-3-amines. *Bioorg. Med. Chem.* 2012, *20*, 5850– 5863, doi:https: 10.1016/j.bmc.2012.07.052. [b] Al-Tel, T.H.; Al-Qawasmeh, R.A.; Zaarour, R. Design, synthesis and in vitro antimicrobial evaluation of novel Imidazo[1,2-a]pyridine and imidazo[2,1b][1,3]benzothiazole motifs. *Eur. J. Med. Chem.* 2011, *46*, 1874–1881, doi:https: 10.1016/j.ejmech.2011.02.051.
 [c] Starr, J.T.; Sciotti, R.J.; Hanna, D.L.; Huband, M.D.; Mullins, L.M.; Cai, H.; Gage, J.W.; Lockard, M.; Rauckhorst, M.R.; Owen, R.M.; Lall, M.S.; Tomilo, M.; Chen, H.; McCurdy, S.P.; Barbachyn, M.R. 5-(2-Pyrimidinyl)-imidazo[1,2-a]pyridines are antibacterial agents targeting the ATPase domains of DNA gyrase and topoisomerase IV. *Bioorg. Med. Chem. Lett.* 2009, *19*, 5302–5306, DOI: 10.1016/j.bmcl.2009.07.141.
- McGuinness, B.F.; Cole, A.G.; Dong, G.; Brescia, M.-R.; Shao, Y.; Henderson, I.; Rokosz, L.L.; Stauffer, T.M.; Mannava, N.; Kimble, E.F.; Hicks, C.; White, N.; Wines, P.G.; Quadros, E. Discovery of 2aminoimidazopyridine adenosine A2A receptor antagonists. *Bioorg. Med. Chem. Lett.* 2010, 20, 6845–6849, DOI:10.1016/j.bmcl.2010.08.064.
- 25. El-Sayed, W.M.; Hussin, W.A.; Al-Faiyz, Y.S.; Ismail, M.A. The position of imidazopyridine and metabolic activation are pivotal factors in the antimutagenic activity of novel imidazo[1,2-a]pyridine derivatives. *Eur. J. Pharmacol.* **2013**, *715*, 212–218, DOI: 10.1016/j.ejphar.2013.05.018.
- [a] Grädler, U.; Fuchß, T.; Ulrich, W.-R.; Boer, R.; Strub, A.; Hesslinger, C.; Anézo, C.; Diederichs, K.; Zaliani, A. Novel nanomolar imidazo[4,5-b]pyridines as selective nitric oxide synthase (iNOS) inhibitors: SAR and structural insights. *Bioorg. Med. Chem. Lett.* 2011, *21*, 4228–4232, DOI: 10.1016/j.bmcl.2011.05.073. [b] Phillips, D.J.; Davenport, R.J.; Demaude, T.A.; Galleway, F.P.; Jones, M.W.; Knerr, L.; Perry, B.G.; Ratcliffe, A.J. Imidazopyridines as VLA-4 integrin antagonists. *Bioorg. Med. Chem. Lett.* 2008, *18*, 4146–4149, DOI: 10.1016/j.bmcl.2008.05.075.
- 27. T.S. Harrison, G.M. Keating, Zolpidem: A review of its use in the management of insomnia(Review) *CNS Drugs*, 19 (2005), pp. 65-89, DOI: 10.2165/00023210-200519010-00008.
- 28. Kishore, K.G.; Islas-Jácome, A.; Rentería-Gómez, A.; Conejo, A.S.; Basavanag, U.M. V; Wrobel, K.; Gámez-Montaño, R. Synthesis of unsymmetrical bis-heterocycles containing the imidazo[2,1-b]thiazole framework and their benzo[d]fused analogues by an acid-free Groebke–Blackburn–Bienaymé reaction. *Tetrahedron Lett.* **2016**, *57*, 3556–3560, DOI: 10.1016/j.tetlet.2016.06.120.
- 29. Title of Site. Available online: URL (accessed on Day Month Year).



© 2018 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).